Compare NNNN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | PGEN |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2025 | N/A |
| Metric | NNNN | PGEN |
|---|---|---|
| Price | $33.50 | $4.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 37.4K | ★ 5.2M |
| Earning Date | 04-28-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $6,920,153.00 | $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | $554.67 | ★ N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $5.18 | $1.08 |
| 52 Week High | $55.65 | $5.23 |
| Indicator | NNNN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 54.16 |
| Support Level | $32.93 | $4.03 |
| Resistance Level | $43.00 | $4.48 |
| Average True Range (ATR) | 4.09 | 0.34 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 33.23 | 48.53 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.